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Severe community acquired pneumonia
Early switch from intravenous to oral antibiotics is safe and reduces hospital stay
Research into community acquired pneumoniaover the past two decades has focused ondeveloping tools to measure the severity of ill-
ness and which antibiotics to choose. Several tools can
now help clinicians identify patients with severe
community acquired pneumonia in clinical settings.1 In
people with severe disease, international guidelines
recommend early treatment with broad spectrum anti-
biotics, which provide cover for atypical pathogens.2
It is less clear how best to manage patients during
their stay in hospital. In this week’s BMJ, a randomised
trial by Oosterheert and colleagues reports the effect
of switching from intravenous to oral antibiotics after
three days rather than seven days in people with severe
community acquired pneumonia.3 Until now, the lack
of quality trial data in areas such as route of antibiotic
administration, duration of treatment, and assessment
of clinical stability has led to a conservative approach
to management and prolongation of hospital stay.
The National Health Service spends more than
£400m (€592m; $780m) a year on community
acquired pneumonia.4 To reduce healthcare costs,
length of hospital stay should be reduced without com-
promising patient safety. Our group has shown that cli-
nicians’ behaviour is the main determinant of
variability in the duration of treatment with intrave-
nous antibiotics. It outweighs all other factors,
including patient characteristics, and is therefore the
major determinant of length of hospital stay for
patients with this disease.5 Provision of quality data is
key to reducing the pronounced variability in clinical
practice.
The trial by Oosterheert and colleagues provides
more support for an early switch from intravenous to
oral antibiotics. It found that such a switch was safe and
reduced length of hospital stay (9.6 v 11.5 days; 95%
confidence interval 0.6 to 3.2).5 One strength of the
study was that it used clinical stability as the basis for
switching from intravenous to oral treatment in the
intervention arm. The time chosen to switch patients
from intravenous to oral antibiotics was three days if
clinical stability criteria were met (including respiratory
rate < 25 per minute, haemodynamic stability, and
ability to take oral drugs). Data on the minimum safe
duration of intravenous antibiotics in this context are
still to be determined. During follow-up, only 2% of
patients who were switched to early oral antibiotics
needed to restart intravenous therapy.
The other aspect of the study relevant to length of
stay was the delay of about five days to discharge
despite patients meeting predefined discharge criteria.
This occurred even though the discharge criteria were
more conservative than the stability criteria used for
the intravenous to oral switch. The treating physician
decided the time of discharge, and this decision will
have been influenced by social factors and comorbidi-
ties specific to each patient. The authors suggest that
incomplete resolution of all clinical signs of pneumo-
nia delayed discharge even when patients were
clinically stable. However, several observational studies
found no advantage of observing inpatients once
stability criteria comparable to those used in the
current study were met.6 7 This suggests that the
current study used overly conservative discharge prac-
tices, and it would have been safe to shorten length of
stay further for most patients. However, patients must
be stable before discharge, as adverse outcomes have
been reported in people discharged with clinical
instability.8
The challenge now is to design a new era of multi-
centre studies for community acquired pneumonia.
Rather than continuing to search for the best antibiotic
regimen, it is time to answer more pragmatic questions.
Firstly, what degree of clinical stability needs to occur
before switching to oral antibiotics given the pharma-
cokinetics and recognised modes of action of these
drugs?9 If most (81%) patients safely tolerated the
switch from intravenous to oral antibiotics after three
days then some may have tolerated the switch earlier;
possibly at the first sign of clinical improvement or
even after the first dose. Secondly, would further inves-
tigation of the criteria for clinical stability, combined
with strategies that deal with social determinants, facili-
tate further reductions in length of stay without
compromising patient safety or satisfaction? We have
sufficient evidence to ensure that research into these
questions is ethical.
The results of the study should give clinicians the
confidence to switch clinically stable patients from
intravenous to oral antibiotics at 72 hours, with consid-
eration of early discharge thereafter. The traditional
one size fits all approach to the management of
community acquired pneumonia can no longer be
justified.
Graham D Mills infectious diseases physician
(millsg@waikatodhb.govt.nz)
Waikato Hospital, Hamilton, New Zealand 3204
Richard Laing respiratory physician
Christchurch Hospital, Christchurch, New Zealand 8001
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Hajj and the risk of influenza
The threat can no longer be ignored
Atthe end of next month Saudi Arabia will againhost the Hajj—the largest annual gathering inthe world—which attracts more than two
million pilgrims from almost every country on earth.1 2
For the individual pilgrim this is a deeply spiritual
journey that represents the culmination of months if
not years of preparation. From a public health
perspective, however, such a gathering makes the pos-
sible rampant spread of the influenza virus and a
global pandemic—which many experts believe is
overdue—a potentially devastating prospect that has
been inadequately prepared for.3
Recent work highlighting the high rates of
infection and carriage of influenza virus in pilgrims
returning from Mecca has emphasised the need for
internationally agreed strategies to minimise the risk of
a pandemic.4–6 Such a strategy should centre on ways to
prevent transmission, but must also include facilities
for prompt diagnosis and treatment of infected
individuals. No such comprehensive strategy currently
exists.
The Hajj and its associated rites are a once in a life-
time obligation for people who have the means to
undertake the journey. The Hajj attracts ever
increasing numbers of men, women, and children from
a diverse array of ethnic, linguistic, and social
backgrounds.1 2 Because the sacred rites are under-
taken at the same time, overcrowding is considerable
throughout the five day Hajj period. Accommodation
is, of necessity, in tents in the desert plains of Mina and
Arafat, and it is not unusual for 50-100 people to share
a tent overnight. Such overcrowding and continuous
close contact greatly increases the spread of respira-
tory infections. It has been estimated that more than
one in three pilgrims will experience respiratory
symptoms during their stay.4
The Saudi Arabian Ministry of Health has
recommended that masks be used to minimise droplet
spread,7 8 but many Muslims consider covering the face
during the Hajj to be prohibited. In addition, masks
need to be of a high quality and changed at least every
six hours to remain effective, so general compliance
with this advice is unlikely.
The Department of Health (for England) does not
advise the use of masks, but frequent hand washing is
recommended to reduce spread of the virus. Given the
religious insistence on ritual purity before the five daily
prayers and other acts of worship, this suggestion
should be acceptable to most pilgrims and relatively
easy to implement.9
Although the Saudi authorities currently recom-
mend vaccination against influenza for pilgrims with
“high risk” chronic illnesses such as pre-existing respi-
ratory disorders, data from the United Kingdom indi-
cate that many such high risk pilgrims remain
unimmunised.10 The situation is probably far worse
among the large numbers of people coming from the
economically developing world. Given this fact and
the risks of a pandemic originating from the Hajj,
mandatory influenza vaccination for all pilgrims
should be considered.11 Mandatory meningococcal
vaccination was introduced after a meningococcal epi-
demic among pilgrims and their contacts. As pilgrims
already need to seek medical attention to obtain a
meningococcal vaccination, this extra vaccination
should not be too inconvenient and should be readily
acceptable.
Neuraminidase inhibitors can reduce the duration
of the illness and its spread to household contacts.12
However, two practical difficulties need to be
overcome before these drugs can be made available to
pilgrims. Firstly, the high prevalence of general
respiratory symptoms and the absence of state-of-the-
art diagnostic testing facilities make it difficult for
infected people to be identified quickly.5 Early diag-
nosis is important for treatment to be effective, so near
patient testing should be more readily available. The
second difficulty lies in the cost of stock piling
sufficient supplies for the numbers that may be
affected and the logistical challenge of ensuring that
household contacts of returning pilgrims are treated
promptly.
Virus surveillance studies to identify newly emerg-
ing strains are needed urgently. Currently Saudi Arabia
is not among the 100 centres around the world where
such structured surveillance studies are being
undertaken.4 The World Health Organization is still
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developing its strategy to prevent a possible influenza
pandemic. WHO must work with the Saudi authorities
to minimise the risk of the influenza virus spreading
among pilgrims (and the rest of us). A coherent inter-
national response will be needed to ensure that the
resources and logistics are in place so that these strate-
gies can be implemented.13
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Shuja Shafi consultant microbiologist
Clinical Microbiology and Health Protection Agency Collaborating
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Child safety in cars
Good practice is now reinforced by new legislation
In 2005 in the United Kingdom, 24 children agedunder 10 years were killed while travelling in carsand a further 226 were admitted to hospital.1 The
numbers of injured children who were wearing baby
and child restraints or seat belts were not given, but
such devices are known to be effective in reducing the
severity of injury.2–4 When used properly, child passen-
ger restraints reduce injury by 90-95% for rear facing
systems and 60% for forward facing systems compared
with not using a restraint.5
On 18 September 2006 the law on carrying babies
and children in cars, vans, and goods vehicles in the
UK changed to correspond with the rest of the
European Union. Limited use of child restraints and
seat belts in cars in the UK has been required by law
since 1983 in the front seat and 1989 in the rear seat.
However, the UK adopted a minimalist approach—
baby and child seats had to be used only if one was
available in the vehicle—a fact not widely publicised for
obvious safety reasons. The legislative changes
reinforce what should always be good practice: that all
children in cars should use appropriate child restraints
and that adult seat belts are intended for adults, not
children.
The law states that children under 3 years cannot
legally travel in cars unless they are in an appropriate
baby or child seat (usually a rear facing baby seat for
children under 1 year and a child seat with an integral
harness for older children). The one exception is when
a baby or young child is carried in a taxi and no child
restraint is available; in these circumstances the child
may travel unrestrained on the back seat.
The law is more complicated for children over 3
years.When a child is 12 years old or reaches 1.35 m an
adult seat belt can be used without increasing the risk
of injury. Children under 12 years who are less than
1.35 m tall are now required to use appropriate child
restraints. Such restraints are child seats with integral
harnesses or so called booster seats, in which the adult
seat belt passes around the front of the child; the func-
tion of the booster seat is to position the belt correctly
on the child’s body.
There is one exception for children over 3 years,
the “unexpected necessity” clause. This clause allows
children to use an adult seat belt for an unplanned but
necessary short journey if a child restraint is not avail-
able. The Department for Transport emphasises that
this is not intended to cover regular school runs but is
applicable when, for example, a child cannot be
collected as planned and alternative arrangements are
made at short notice. When the alternative to using an
adult seat belt is leaving the child outside the school
gate the exemption seems sensible, although it should
be monitored through observational studies commis-
sioned by the Department for Transport to detect
abuse.
Failure to comply with the law can result in a £30
(€44; $59) fixed penalty notice or a fine of up to £500 if
the case goes to court. Although policing of the child
restraint law has been barely visible in the past, in 2004
around 200 000 fixed penalty notices were issued. How
strongly the police intend to (or need to) enforce the
recent changes remains to be seen. A constructive
approach will probably be taken initially, with police
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forces working with local authority road safety officers
to ensure that parents and carers understand the law.
Police officers are unlikely to start carrying height
measuring equipment in their cars to enforce the
detailed provisions of the law.
Despite changes in the past 10 years, child
restraints are still not that easy to use consistently.
Child seats with Isofix attachments that are plugged
into corresponding anchorages in cars are becoming
more common in the UK. This system decreases the
likelihood that the seat will be fitted incorrectly, but
such seats can be twice the price of those restrained by
an adult seat belt. Although not an argument against
using Isofix, this is an example of poorer families being
disadvantaged compared with better off families by the
cost of technological development.
Although the change to the legislation is welcome,
we must remember that child restraints and seat belts
are secondary safety measures. They have the
potential, when fitted correctly and used consistently,
to reduce the severity of injuries and the likelihood
of death. They do not prevent car crashes, however,
and prevention should continue to be the long term
aim.
Michael Hayes projects director
(mike.hayes@capt.org.uk)
Child Accident Prevention Trust, London EC1R 3AJ
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Treatment of dementia in the community
Occupational therapy improves function and reduces the burden on care givers
The paper by Graff and colleagues in this week’sBMJ comes at a time of disappointment andconfusion for people with dementia and for
those who care for them.1 The National Institute for
Health and Clinical Excellence (NICE) recently recom-
mended that cholinesterase inhibitors should not be
used in patients with mild dementia, on the grounds
that the modest benefits of treatment do not justify the
healthcare costs.2 The hope that atypical antipsychotic
drugs might play an important role in the manage-
ment of non-cognitive aspects of dementia has been
thwarted by evidence of adverse cerebrovascular
events and increased mortality.3 Against this back-
ground, Graff and colleagues’ study provides hope for
effective non-pharmacological interventions and an
example of how to design research into care for
dementia.
The trial participants comprised 135 people
with mild to moderate dementia who were living in
the community. It found that a five week occupational
therapy intervention (about 18 hours for each patient
and care giver) significantly increased the functioning
of the patient and reduced the burden on the care
giver. The number needed to treat to produce a
clinically significant improvement in patients’ function
and burden to care givers at six weeks was impressively
low. For patients’ daily functioning, the number
needed to treat was 1.3 (95% confidence interval 1.2 to
1.4) when the assessment of motor and process skills
scale was used, and 1.5 (1.4 to 1.6) if the interview of
deterioration in daily activities in dementia scale was
used. For burden on care givers, as assessed by the
sense of competence questionnaire, the number
needed to treat was 2.5 (2.3 to 2.7). Furthermore, the
benefits were maintained at three months.
The trial is noteworthy in three respects—the
choice of the target population, the type of
intervention, and the definition of treatment outcome.
The target population comprised people living with
dementia and their carers. Most people with dementia
live in the community and have mild to moderate dis-
ease. Almost all have a primary care giver. The care
giver’s role is crucial, as the daily functioning of people
with dementia depends on the quality of care received
at home.4 The quality of the relationship with the care
giver is an important predictor of whether someone
with dementia will stay in the community or enter an
institution.5 By focusing the intervention on both the
patient and their carer, Graff and colleagues have
looked at this crucial relationship in the community
setting.
The intervention comprised a personalised pro-
gramme in which patients and care givers learnt to
choose and prioritise meaningful activities they wanted
to improve. The therapist then helped them develop
optimisation and compensation strategies that effec-
tively used their skills and personal and environmental
resources. Thus, the intervention was not just tailored
to the circumstances of the patient and their carer but
also to their values and aspirations.
The methodology reflects the integrated approach
adopted by occupational therapists supporting people
with dementia and their carers. The trial justifies such
an approach and points to how it can be optimised.
This “selection optimisation compensation” model can
identify strategies associated with healthy ageing in the
population.6 7 The current study shows that this
approach can also be used to develop effective
interventions to help people adapt to the demands of
dementia, despite their limited learning abilities.
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The study end points focused on patient function
and the wellbeing of care givers. People with dementia
and their care givers will recognise these end points
as valid. The association of these outcomes with the
risk of entering institutional care makes them impor-
tant for appraising the impact of the intervention on
healthcare costs. The trial shows that the primary
focus of research should be the patient and their carer,
and that interventions and outcomes must reflect this.
Importantly the patients in the study were already
stable on cholinesterase inhibitors at the outset. The
benefits of the intervention are therefore in addition to
those of medication. It would be interesting to assess
the effect of the intervention in the absence of
cholinesterase inhibitors or to compare it with a
cholinesterase inhibitor in a head to head trial.
Non-pharmacological interventions in dementia
have a long history, but until recently they have not
been tested in high-quality controlled trials.8 This is
unfortunate because interventions such as the one
described by Graff and colleagues have the potential to
deliver additional benefits to those obtained with drugs
alone, as they encompass the patient, their carer, and
their environment.
The promising results of this study need to be
replicated, and further trials need to be refined and
extended. This requires building research capacity
and increasing resources and funding to the multi-
disciplinary teams that deliver care for dementia in the
community. To achieve this goal, however, we need to
deal with the complex factors that have caused
non-pharmacological research into dementia to lag so
far behind its pharmacological counterpart. We also
need to examine the structure and funding of research
to bring it closer to the Alzheimer’s Society’s vision of
a proportionate balance between cause, care, and
cure.9
Jeannette Golden senior registrar in old age psychiatry
(jeannette.golden@gmail.com)
Brian Lawlor Conolly Norman professor of old age
psychiatry
St James’s Hospital and Trinity College, Dublin, Ireland
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The future of primary care nurses and
health visitors
Increasing fragmentation threatens the primary healthcare team
New policies, new contracts, and financialpressures have altered the roles of primarycare nurses and health visitors and their
relationship with general practitioners (GPs). How will
the primary care trust survive?
Roles in different countries
In remote areas of some rich nations (such as rural
Australia) highly trained nurses provide the core of
primary medical care for adults and children. In many
developing nations (such as Bangladesh and China)
locally trained nurses tend to work in hospitals and
private clinics in towns, whereas health care in rural
communities often depends on lay medical aides and
occasionally doctors. In the United States nurses man-
age care for chronic disease.1
In the United Kingdom, some nurses are
employed by independent contractor GPs, while
others including health visitors are attached to general
practice teams but are paid and managed by primary
care organisations. They have worked alongside
GPs for many years: good communications between
such primary care professionals lead to better quality
care for patients with complex clinical and social
problems.
Alternative ways of working
Pressure to save money, improve patient access, and
tackle shortages in the medical workforce has led the
UK government to develop alternatives to traditional
general practice. These include National Health
Service (NHS) walk-in centres, NHS Direct, primary
care trust medical services, and alternative provider
medical services. These changes threaten the tradi-
tional primary healthcare team and raise questions
about the future of primary care nursing and health
visiting.
Nurses and health visitors are withdrawing from
primary healthcare teams in England for two
main reasons. Firstly, their numbers are declining. A
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third of primary care nurses and health visitors are
approaching retirement age,2 and training restrictions,
vacancy freezes, and staff cuts have exacerbated the
shortfall. The number of health visitors is the lowest
for 12 years.3 Recent proposals in Scotland advocate
that specialist community nurses and health visitors
are replaced by generic community nurses.4 In
England, some health visitors have moved to new chil-
dren’s centres. The recruitment of “community
matron” managers from district nursing has also left
gaps in the primary care nursing workforce.
Increasing competition
Secondly, primary healthcare trusts are threatened by
competition, which has altered the way that primary
care providers view each other. The UK government is
keen to develop alternative ways of providing health
care, and by stimulating competition it hopes to
improve quality and value for money. Clinical services
run mainly by nurses and nurse practitioners are
thought to provide better access for patients at less
cost. Such nurses may take on senior posts with
considerable strategic and operational responsibility.
In England, practice based commissioning, with
general practices taking control of budgets for second-
ary care services, may stimulate other innovations
where privately or self employed nurses work for
specialist services.
None the less, other factors may encourage nurses
to remain in primary healthcare trusts led by GPs. Pri-
mary care nurses see an opportunity to become entre-
preneurs5 as alternative (private) providers embracing
“social enterprise.” However, they are hesitant to leave
the clinical support, relative financial security, and pen-
sions provided by the NHS. In addition, the 2003 GP
contract6 has stimulated many practices to think about
staffing and skill mix,7 which has led to initiatives to
improve the professional status of nurses. New systems
that reward practices for good management of chronic
diseases have highlighted the financial and clinical
importance of input from nurses. Many general
practice nurses are acquiring advanced skills in
diagnosis and prescribing; others are taking strategic
and leadership roles or even becoming practice
partners.
Targeted health promotion
Fitzpatrick8 suggests that many aspects of promoting
healthy lifestyles could carry on outside general
practice with lay trainers so that GPs and primary care
nursing professionals would have more time for
patients with acute and chronic diseases. Although
general practice does need to define its boundaries
regarding social care and education, we think that tar-
geted promotion led by nurses still has a place in gen-
eral practice.
It is time to re-examine the divisions of power,
responsibility, and rewards within general practice pri-
mary healthcare trusts. We believe that such trusts
should remain central to the provision of primary care
but wonder whether changes in the role of primary
care nurses and health visitors, and the fragmentation
of the organisations that employ them, will have a
negative effect on patient care and discourage
democratic team work.
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